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Burkholderia mallei (Bm) is a highly infectious intracellular pathogen classified as a
category B biological agent by the Centers for Disease Control and Prevention. After
respiratory exposure, Bm establishes itself within host macrophages before spreading
into major organ systems, which can lead to chronic infection, sepsis, and death.
Previously, we combined computational prediction of host-pathogen interactions with
yeast two-hybrid experiments and identified novel virulence factor genes in Bm,
including BMAA0553, BMAA0728 (tssN), and BMAA1865. In the present study,
we used recombinant allelic exchange to construct deletion mutants of BMAA0553
and tssN (1BMAA0553 and 1TssN, respectively) and showed that both deletions
completely abrogated virulence at doses of >100 times the LD50 of the wild-type Bm
strain. Analysis of 1BMAA0553- and 1TssN-infected mice showed starkly reduced
bacterial dissemination relative to wild-type Bm, and subsequent in vitro experiments
characterized pathogenic phenotypes with respect to intracellular growth, macrophage
uptake and phagosomal escape, actin-based motility, and multinucleated giant cell
formation. Based on observed in vitro and in vivo phenotypes, we explored the use of
1TssN as a candidate live-attenuated vaccine. Mice immunized with aerosolized 1TssN
showed a 21-day survival rate of 67% after a high-dose aerosol challenge with the wild-
type Bm ATCC 23344 strain, compared to a 0% survival rate for unvaccinated mice.
However, analysis of histopathology and bacterial burden showed that while the surviving
vaccinated mice were protected from acute infection, Bm was still able to establish
a chronic infection. Vaccinated mice showed a modest IgG response, suggesting a
limited potential of 1TssN as a vaccine candidate, but also showed prolonged elevation
of pro-inflammatory cytokines, underscoring the role of cellular and innate immunity in
mitigating acute infection in inhalational glanders.
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INTRODUCTION
Burkholderia mallei (Bm) is the etiological agent of glanders
(Boerner, 1882) and is classified as a Category B biological
agent by the Centers for Disease Control and Prevention.
Horses, donkeys, and mules are considered the natural host
for Bm infection and serve as reservoirs for transmitting the
disease to other animals and humans (Sharrer, 1995). Human
infection, although rare, is almost always fatal without antibiotic
intervention. While the most likely route of infection for Bm
is contact with mucus discharge of an infected animal, Bm is
also highly infectious by aerosol (Howe and Miller, 1947) and is
considered to have potential use as a biological weapon (CDC
Strategic Planning Workgroup, 2000). Bm infections have been
shown to be highly resistant to antibiotics, and there is currently
no approved vaccine for glanders.
Bm is a facultative intracellular pathogen that establishes itself
in host macrophages after either respiratory or subcutaneous
exposure (Howe and Miller, 1947; Srinivasan et al., 2001),
resulting in an acute infection, followed by dissemination to
major organ systems, chronic infection, sepsis, and death. Bm
is equipped with an extensive set of mechanisms for invasion
and modulation of host cell environments. Key mechanisms of
Bm pathogenicity are encoded in virulence factors, proteins that
control and promote pathogenic internalization, survival, and
replication within host cells (Galyov et al., 2010; Allwood et al.,
2011). A number of virulence factors have been characterized
and play roles in adhesion, endosomal escape, evasion of host
cell autophagy, actin-based motility, multinucleated giant cell
(MNGC) formation, and replication (Nierman et al., 2004;
Stevens et al., 2005a; Schell et al., 2007; Galyov et al., 2010;
Losada et al., 2010; Lazar Adler et al., 2011; Memiševic et al.,
2013).
In previous studies, we used a combined computational and
experimental strategy to systematically identify and characterize
the interaction between Bm virulence factors and their host
targets (Memiševic et al., 2013, 2015). We used several
bioinformatics approaches to select a small number of putative
and known virulence factors and used yeast two-hybrid
assays to determine their interacting partners in human and
murine hosts. The analysis of these host-pathogen interactions
allowed us to identify three novel Bm virulence factor genes,
BMAA0553, BMAA0728 (tssN), and BMAA1865, and show that
insertion mutants generated for each of the three virulence
factors attenuated Bm in mouse aerosol challenge experiments
(Memiševic et al., 2013). tssN has been shown to be part of a
gene cluster that encodes components of a type 6 secretion system
(Schell et al., 2007), while little is known about BMAA0553
or BMAA1865. Beyond showing virulence attenuation when
disrupted, none of these three genes have been experimentally
characterized. However, bioinformatics analyses using host-
pathogen interaction data indicate that the tssN plays a role in
ubiquitination and intracellular signaling, BMAA0553 encodes
a putative serine/threonine phosphatase that is involved in
signaling, adhesion, and actin cytoskeletal rearrangement, and
that BMAA1865 plays a role in ubiquitination and phagosomal
escape (Memiševic et al., 2014, 2015).
Attenuated strains can be used as live-attenuated vaccines
(LAVs) that establish mild infections in the host, mimicking the
infection of fully virulent wild-type (WT) strains and presenting
appropriate antigens to the host immune system to induce
durable antibody and cell-mediated immune responses (Drabner
and Guzman, 2001). LAV candidates for both Bm (Ulrich et al.,
2005; Mott et al., 2015) and the closely related Burkholderia
pseudomallei (Bp) (Breitbach et al., 2008; Norris et al., 2011;
Silva et al., 2013) are among the most promising Burkholderia
vaccines to date; although some have demonstrated protection
against acute infection, all consistently failed to completely
prevent the establishment of chronic infection in the BALB/c
mouse model (Ekström et al., 2013). Unimmunized BALB/c mice
challenged by a lethal dose of Bm die within several days of
exposure. LAV immunization can extend their survival beyond
the acute stage of the infection, but 100% mortality is observed
by 60 days. Finally, unlike naturally occurring or laboratory-
passaged attenuated strains, genetically engineered strains can
have well-definedmechanisms of attenuation, making them safer,
better-characterized alternatives as candidate LAVs (Bozue et al.,
2012).
As an extension of our previous study (Memiševic et al.,
2013), we sought to use recombinant allelic exchange to engineer
Bm deletion mutants for the virulence factors BMAA0553, tssN,
and BMAA1865 to characterize pathogenic phenotypes and
explore their potential as LAVs. The insertion mutants generated
previously (Memiševic et al., 2013) have two drawbacks: (1)
the observed attenuation could have resulted from unintended
disruption of genes downstream of the target gene and (2)
the potential for the insertion mutant to revert to wild-type,
limiting its potential as a candidate vaccine. Here, we successfully
engineered in-frame deletion mutants for BMAA0553 and tssN
(termed1BMAA0553 and1TssN, respectively). We assessed the
pathogenicity of1BMAA0553 and1TssN after aerosol exposure
in BALB/c mice, characterized pathogenic phenotypes in in vitro
infection models, evaluated the efficacy of 1TssN as an LAV,
and identified immune responses that may be associated with
protection against glanders.
MATERIALS AND METHODS
Bacterial Strains and Media
The Escherichia coli and Bm strains and plasmids used in this
study are shown in Supplementary Table 1. All E. coli strains
were grown at 37◦C on Luria-Bertani (LB) Lennox medium.
Bm was grown on sheep blood agar plates or LB Lennox broth
agar plates containing 4% glycerol. As indicated, antibiotics
were used at the following concentrations: ampicillin, 50µg/ml;
kanamycin, 50µg/ml; and polymyxin B, 15µg/ml. After conjugal
mating and animal challenges, we performed screening on
Burkholderia cepacia agar (R01709, Remel Inc., Lenexa, KS) to
confirm the presence of Bm. We performed this work at the
United States Army Medical Research Institute of Infectious
Diseases (USAMRIID), which is compliant with all Federal and
Department of Defense regulations pertaining to the use of Select
Agents.
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Construction of 1BMAA0553 and 1TssN
Mutants
To delete the BMAA0553 gene from Bm, we initially tried
to use PCR to amplify BMAA0553 from Bm genomic DNA
but had difficulty producing the correct PCR product. Instead,
we resorted to using the homologous gene, BPSS0403, from
the K96243 strain of Bp. The DNA fragment containing
BPSS0403 and its flanking region has 100% sequence identity
to BMAA0553. The gene and flanking DNA was amplified
from genomic DNA using Taq DNA polymerase and GC buffer
(Qiagen Inc., Gaithersburg, MD) and cloned into the pCR2.1
plasmid. The resulting plasmid was digested using NruII, which
removed an internal 546-bp fragment from the gene, and then
re-ligated. The excised fragment containing the remaining 429-
bp of the upstream and 486-bp of the downstream gene was then
cloned into the NheI site of pMo130 (Hamad et al., 2009).
To delete tssN, the DNA fragment containing the gene and
the flanking DNA was amplified using PCR from Bm genomic
DNA. We ligated the PCR product into pWSK30 (Wang and
Kushner, 1991) and removed the tssN gene from the plasmid
through inverse PCR, in frame, retaining the first and last three
nucleotides of the gene. We cloned the fragment containing the
deletion into pJET2.1 (Fermentas Inc., Glen Burnie, MD) and
then subcloned it into pMo130.
We attempted to carry out an in-frame deletion of BMAA1865
but were unable to do so due to the presence of a 21-bp repeat
sequence that is repeated 37 times upstream of BMAA1865.
This repeat prevented PCR amplification of this region and
construction of an in-frame deletion plasmid.
The pMo130-1tssN and pMo130-1BMAA0553 plasmids
were transformed into E. coli strain S17-1 (Simon et al., 1983)
and mobilized via conjugation into Bm GRS 23344, a 1sacB
deletion mutant derived from ATCC 23344 (Schell et al., 2008).
We performed the mating procedure to initially select for
cointegrates as previously described (DeShazer et al., 2001). To
select for allelic exchange mutants, we grew the Bm cointegrate
strain in yeast-extract tryptone (YT) broth medium and then
serially diluted it onto YT agar plates +5% sucrose. We screened
colonies that grew in the presence of sucrose for the loss of
kanamycin resistance (present on pMo130), and verified the
deletions by PCR. All primers used in this study are detailed in
Supplementary Table 2.
Extracellular and Intracellular Growth
Assays
To examine growth in media, bacterial strains were grown
overnight in LB, LB + 4% glycerol, or M9minimal medium
(supplemented with glucose at final concentration of 0.2%)
and re-suspended in fresh broth to approximately equal optical
density (OD). We established growth as an increase in the
absorbance at an OD 600 nm (OD600) using an Infinite M200
pro (Tecan, Männedorf, Switzerland) microplate reader in 96-
well microtiter plates. We analyzed quadruplicate samples and
included uninoculated controls to confirm sterility.
For intracellular growth assays, we grew Bm in LB Lennox
broth + 4% glycerol for 15–18 h. RAW 264.7 cells were
maintained in DMEM with 6mM L-glutamine and 10% fetal
bovine serum at 37◦C with 5% CO2. To study intracellular
replication, we plated 2×105 RAW 264.7 cells into 24-well tissue
culture plates and cultured them for 2 days. The cells were then
infected at the multiplicity of infection (MOI) of less than 10
bacteria per macrophage. After 1 h, cells were washed twice with
PBS and then reincubated in cell culture media with 200µg/ml
gentamycin. At the times indicated, macrophage cells were lysed
with 0.2% Triton X-100, serially diluted, and plated onto agar
plates for colony forming unit (CFU) counts.
Immunofluorescence Staining and
Confocal Microscopy
To examine phagosomal escape and actin tail formation, we
seeded 2 × 105 RAW 264.7 cells on a 12-mm no. 1-1/2 coverslip
(Electron Microscopy Sciences, Hatfield, PA) and infected them
at a MOI of 20 the following day. For MNGC formation
experiments, we seeded 4× 105 cells onto coverslips and infected
them at a MOI of 5 the following day. To remove extracellular
bacteria, coverslips were washed vigorously with PBS after the
1 h infection. Coverslips were placed in antibiotic-free medium
and further incubated for the times indicated. Cells were fixed
with 4% paraformaldehyde and then blocked in PBS containing
0.25% saponin, 0.2% Bovine Serum Albumin (BSA) fraction
V, and 0.2% fish skin gelatin (Sigma-Aldrich, St. Louis, MO)
for 2 h. Cells were subsequently incubated with rabbit anti-
Burkholderia antibody (1:1000) (D. Waag, USAMRIID) and/or
rat anti-lysosomal associated membrane protein 1 (LAMP-
1) (1:200) antibody (ID4B; Developmental Studies Hybridoma
Bank, Iowa City, IA) overnight at 4◦C. After being washed,
cells were incubated with secondary antibody conjugated to
a fluorophore (1:600, Jackson Immunoresearch, West Grove,
PA) for 5 h. Cells were also stained with phalloidin and/or
4′,6-diamidino-2-phenylindole (DAPI, Life Technologies, Grand
Island, NY) for 2 h before the coverslip was mounted with
Fluoromount G (Electron Microscopy Sciences, Hatfield, PA).
Separate sets of coverslips were used to score for LAMP-1 and
actin localization. Confocal microscopy was performed on the
Zeiss 700 Laser Scanning Microscopy System using Zen-Black
Edition 2011 software (Carl Zeiss Microimaging, Thornwood,
NY). MNGC images were collected using the ×40 (numerical
aperture: 1.3) oil objective lens, whereas the ×100 (numerical
aperture: 1.4) oil objective lens was used for phagosomal escape
and actin tail experiments. The pinhole was set to∼1 Airy unit.
Animal Challenges
For all challenges, we prepared a suspension of Bm using
LB Lennox broth + 4% glycerol. Broth cultures were grown
overnight in a 37◦C shaker at 150 rpm and adjusted for
various challenge doses as determined by serial dilutions and
plating. Female BALB/c mice (7–9 week old), obtained from the
National Cancer Institute, were anesthetized via an intramuscular
injection with ketamine, acepromazine, and xylazine. We carried
out intranasal challenge for Bm strains ATCC 23344 and GRS
23344 by intranasal instillation with 50µl of Bm suspended in
PBS to compare the virulence of the two strains.We administered
aerosolized doses of ATCC 23344, GRS 23344,1BMAA0553, and
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1TssN using a dynamic 30-liter humidity-controlled Plexiglas
whole body exposure chamber, as previously described (Roy et al.,
2003).We obtained an estimate of the inhaled doses as previously
described (Glynn et al., 2005; Dabisch et al., 2012a,b). For all
challenge experiments, mice were monitored several times each
day, and mortality rates (or euthanasia when moribund) were
recorded.
Aerosol-challenged mice (n = 5) were euthanized within
a CO2 chamber at the specified time postinfection for
Bm dissemination experiments. The lungs and spleens were
harvested, rinsed, weighed, and then homogenized in 1ml
PBS using a tissue grinder (Kendall Healthcare Precision
Disposable Tissue Grinder Systems, Covidien, Mansfield, MA).
Homogenates were then serially diluted and plated on to sheep
blood agar plates to determine CFU recovery.
Vaccination Experiments
Blood was collected from all mice via submandibular bleeding
before the initiation of the experiments to obtain pre-immune
sera. Mice were split into the following groups: a naïve, untreated
control group (n = 10) and a vaccination group (n = 39).
Vaccinated mice received a primary aerosol immunization of
1TssN at day 0 followed by boost aerosol immunizations at
day 21. Vaccinated mice (n = 15) at day 42, along with naïve
control mice, were challenged with an aerosolized dose of the
fully virulent Bm strain ATCC 23344 (4.3 × 104 CFUs, or 43
LD50) and followed for 21 days to compare survival and time
to death between groups. In order to monitor the bacterial
dissemination, pathology, and immune responses induced by
1TssN immunization, a subset of vaccinated mice (n = 5) were
euthanized by CO2 exposure for pathology and CFU detection
from various organs and a second subset of vaccinated mice (n =
5) were euthanized by exsanguination under deep anesthesia to
obtain sera for testing antibody levels and spleens to perform
splenocyte stimulation assays following each of the three aerosol
immunizations.
Animal research at the United States Army Medical Research
Institute of Infectious Diseases (USAMRIID) was conducted
under an animal use protocol approved by the USAMRIID
Institutional Animal Care and Use Committee in compliance
with the Animal Welfare Act, Public Health Service Policy, and
other federal statutes and regulations relating to animals and
experiments involving animals. The facility where this research
was conducted is accredited by the Association for Assessment
and Accreditation of Laboratory Animal Care, International and
adheres to principles stated in the 8th Edition of the Guide for the
Care and Use of Laboratory Animals, National Research Council,
2011.
Immunological Assays
Antibody Assay
The antibody titers in vaccinated mice were determined as
previously described (Amemiya et al., 2002). Briefly, IgG, IgG1,
and IgG2a titers in sera were determined by an ELISA using
96-well plates (Immulon 2 HB, round bottom, Fisher Scientific,
Pittsburgh, PA). Irradiated Bm strains were diluted in 0.1M
carbonate buffer (pH 9.5) to a concentration of 10µg/ml. Then,
50µl of the diluted bacteria was placed into wells, and plates were
incubated at 4◦C overnight. Plates were washed with washing
solution (1× PBS and 0.05% Tween 20) and incubated with
100µl of blocking solution (washing solution with 1% BSA) for
1 h at 37◦C. Two-fold dilutions of mouse sera were made with
blocking solution in triplicate, and plates were incubated for
1 h at 37◦C. After the plates had been washed, 50µl of 1:5000-
diluted anti-Ig-horseradish peroxidase conjugate for IgG, IgG1,
or IgG2a (Southern Biotechnology Associates, Inc., Birmingham,
AL) were added to each well, and plates were incubated for 1 h
at 37◦C. After the plates were washed, 50µl of a buffered H2O2
and 3,3′,5,5′-tetramethylbenzidine solution (BD Pharmingen,
San Jose, CA) was added to each well, and plates were incubated
for 15min at room temperature. The reaction was stopped with
25µl of 2 N sulfuric acid, and the amount of bound antibody
was determined colorimetrically at 450 nm with a reference filter
of 570 nm. Results are reported as the reciprocal of the highest
dilution giving a mean OD of at least 0.1.
Spleen Cell Preparation
Splenocytes were used for cytokine/chemokine determination
directly from the supernatant in the spleen extracts and after
in vitro stimulation with irradiation inactivated Bm. Splenocytes
were prepared as previously described (Amemiya et al., 2006).
Briefly, spleens were excised from mice and disaggregated in
wash medium (RPMI 1640 medium, Life Technologies, Grand
Island, NY) with 25mM HEPES, 2mM glutamine, 100 U/ml
penicillin and 100µg/ml streptomycin to make the spleen
extract. Aliquots of the spleen extract were stored at −70◦C and
irradiated before cytokine/chemokine determination.
To isolate splenocytes for in vitro stimulation, red blood cells
in the remaining spleen extract were lysed with ACK Lysing
buffer (BioWhittaker, Walkersville, MD) for 5min and diluted
with wash medium. Splenocytes were pelleted by centrifugation
at 1200 rpm for 10min, washed once with complete medium
[wash medium containing 10% heat-inactivated fetal calf serum
(GIBCO, Life Technology, Waltham, MA), 1mM sodium
pyruvate, 0.1mM non-essential amino acids, and 50µM 2-
mercaptoethanol], and splenocytes were suspended in complete
medium and counted.
Stimulation of splenocytes was carried out in 48-well plates
(Costar 3548, Fisher Scientific) with 2 × 106 cells/well in a final
volume of 0.5ml. Splenocytes were stimulated with 2.0 × 107
irradiation-inactivated Bm (ATCC 23344) in complete medium
for 45–48 h at 37◦C and 5%CO2. Phorbol 12-myristate 13-acetate
(PMA; Sigma, St. Louis, MO) with ionomycin (Sigma) at 40 and
500 ng/ml, respectively, were used as a positive control.
Cytokine Analysis
Cytokine analysis was done on both the supernatant from
the spleen extracts and on the supernatant from the in vitro
stimulation of splenocytes. In both cases, samples were
centrifuged at 1200 rpm for 10min, and supernatants were
collected and stored at -70◦C until irradiation. Protein levels
of cytokine/chemokines in the supernatants were measured by
Luminex Mag Pix (Life Technologies, Waltham, MA) as per
the manufacturer’s protocol. The levels of the following 20
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cytokines/chemokines in either spleen extract supernatant or in
the in vitro stimulated splenocyte supernatant were measured:
FGFb, GM-CSF, IFNγ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10,
IL-12, IL-13, IL-17, IP-10, KC, MCP-1, MIG, MIP-1α, TNFα, and
VEGF.
Pathology
Postmortem tissues collected frommice were routinely processed
as previously described. Briefly, tissues were fixed in 10% neutral
buffered formalin, embedded in paraffin, and sectioned for
hematoxylin and eosin (HE) staining. Slides were analyzed at
×200 magnification.
Statistics
Statistical significance was determined by an unpaired two-
tailed Student’s t-test to compare data of intracellular growth,
phagosomal escape, actin tail formation, CFU recovery and
localization experiments from macrophage experiments, and
time-to-death (TTD) and cytokine expression following infection
in mouse experiments, statistical significance. Fifty percent lethal
dose (LD50) analysis was determined by a Bayesian probit
analysis. Survival rates were compared between groups by
Fisher exact tests with permutation adjustment for multiple
comparisons using SAS (version 8.2, SAS Institute Inc., SAS
OnlineDoc, Cary, NC).
RESULTS
Mutant Construction
We deleted the BMAA0553 and tssN genes, in frame, using
double recombination. In order to select for the desired
recombinant, we used Bm GRS 23344 (1sacB sucrose-resistant
derivative strain of ATCC 23344) as the background strain for
generating mutants utilizing pMo130, a shuttle vector, which
contains the sacB gene to select for strains that had resolved
the plasmid in the presence of sucrose. Previous work has
demonstrated that the GRS 23344 strain is as virulent as ATCC
23344, in Galleria mellonella larvae [3]. To further demonstrate
that GRS 23344 is an appropriate background strain for virulence
studies, we compared ATCC 23344 and GRS 23344 strains
in vitro in various types of media and an in vivo murine
pneumonic model of glanders. Growth curves using both a rich
(LB) or minimal (M9) media showed little or no difference
between ATCC 23344 and GRS 23344 (data not shown). LD50
values for both strains were also similar after intranasal challenge
of BALB/c mice (1355 CFU for ATCC 23344 and 1868 CFU for
GRS 23344). In addition, no significant difference between strains
was noted in survival TTD values observed (Supplementary Table
3) except for the lowest challenge dose group. However, the p-
value for this group was based upon the comparison in TTD for
two mice that succumbed to infection with ATCC 23344 and one
mouse that succumbed to challenge with GRS 23344.
To select for deletion mutants of BMAA0553 or tssN in GRS
23344, strains that had undergone allelic exchange and excised
the plasmid (containing sacB) were selected for by growth in
the presence of sucrose. To determine if sucrose-resistant clones
carried the deletion, colonies were screened for the appropriate
gene deletion by PCR with the respective primer pairs. We
observed the full-length PCR product for tssN of∼3 kb, as well as
a 300-bp shift for those clones in which the gene was deleted (data
not shown). Similarly, for BMAA0553 deletion construction, a 4-
kb band was observed for the full-length PCR product, whereas
a 1.5-kb band shift was detected for those strains containing the
gene deletion (data not shown).
We attempted to complement the two mutations by cloning
the respective functional gene including upstream sequence into
pBHR2 (Schell et al., 2007). The E. coli strains carrying the
plasmids and respective functional genes were then transformed
into 1TssN or 1BMAA0553 mutant strains via conjugation as
described above. Kanamycin resistant clones were selected and
the presence of the plasmid was verified by plasmid purification.
However, the mutant strains transformed with the plasmid
containing the functional gene showed abnormal structural
morphology where they were much more elongated/bacillus
in shape as compared to the parent or mutant strains (data
not shown). These transformed strains were confirmed to be
Burkholderia by growth on Burkholderia cepacia agar and reacted
with a Burkholderia antibody (data not shown).
Extracellular and Intracellular Growth
1BMAA0553 and 1TssN deletion strains were analyzed for any
growth defects in LB + 4% glycerol or M9 broth cultures by
OD measurements (Figures 1A,B). We used a logistic growth
equation to fit the data as a function of maximum density, lag
time, and maximum growth rate (Zweitering et al., 1990). For
growth in LB media, we found that 1BMAA0553 did not differ
significantly from GRS 23344 in either maximum density, lag
time or maximum growth rate, while 1TssN showed a modest,
but statistically significantly difference from GRS 23344 in lag
time only, at 7.39 and 6.35 h, respectively (p < 0.001). For growth
inM9media, we observed no differences between GRS 23344 and
either1BMAA0553 or1TssN (Figure 1B).
Next, the ability of 1BMAA0553 and 1TssN to replicate in
host cells was measured. Amacrophage-like cell line (RAW 264.7
cells) was infected and subsequently treated with gentamicin to
kill extracellular bacilli. Figures 1C,D shows that the CFU values
recovered at 24 h for both mutants were approximately 10-fold
less than the parental strain, GRS 23344 (p < 0.001 for both
mutants). However, no defects in uptake were observed for either
of the mutants, as indicated by the 3-h time point.
Phagosomal Escape and Actin Tail
Formation
We investigated the ability of1BMAA0553 and1TssN to escape
the phagosome in infected RAW 264.7 cells by colocalization of
the mutants with LAMP-1 (Sajjan et al., 2006), a protein which
delineates vacuoles of the endocytic pathway. Figures 2A,B
shows that GRS 23344,1BMAA0553, and1TssN were localized
in the LAMP-1 positive phagosome at 2 h postinfection,
but localization in these compartments decreased over time,
suggesting the parental strain and mutants escaped from the
degradative pathway. The rate at which all three strains escaped
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FIGURE 1 | Extracellular and intracellular growth. Bacterial growth, as measured by optical density at 600 nm (OD600), in nutrient-rich LB media +4% glycerol
(LB) and nutrient-limited minimal media (M9) are shown over 24 h for deletion strains 1BMAA0553 (A) and 1TssN (B) compared with the parental strain GRS 23344.
Bacterial growth in RAW 264.7 macrophage-like cells is shown after 3 and 24-h incubation for GRS 23344 and 1BMAA0553 at an MOI of 4 (C), and GRS 23344 and
1TssN at an MOI of 8 (D). Growth was measured in terms of colony forming unit (CFU) recovery using gentamicin protection assays. Error bars represent standard
errors from mean values determined from 2 to 4 replicates/assay. An “**” corresponds to a significant difference at p < 0.001.
was similar, indicating that 1BMAA0553 and 1TssN were
unaltered in their ability to escape the phagosome.
We also examined the ability of 1BMAA0553 and 1TssN
to form actin tails. Both the parental strain GRS 23344 and
1TssN exhibited actin tails at the bacterial poles beginning at 4 h
postinfection and increased in the number of bacteria with tails
to 8 h (Figures 2C,D). This confirms that1TssN has the ability to
escape and polymerize actin. In contrast, no significant actin tail
formation, or nucleation was seen at the poles of 1BMAA0553
bacteria compared to GRS 23344 at 8 h (p < 0.01). Thus, 1TssN
is motile in the cytoplasm, whereas 1BMAA0553 was defective
in actin tail formation.
Multinucleated Giant Cell Formation
We examined the ability of 1BMAA0553 and 1TssN mutants
to induce MNGC formation after infection (Harley et al., 1998;
Brett et al., 2008). RAW 264.7 cells were infected with GRS
23344, 1BMAA0553 or 1TssN at a MOI of 1, immunostained,
and imaged with a confocal microscope (Figure 3). At 6 h post
infection, no MNGC was seen with infection of GRS 23344 or
either mutant. At 24 h, infection with GRS 23344 at an MOI of 1
readily induced MNGC formation that incorporated between 50
and 200 nuclei/cell (Figure 3). In contrast, we observed mostly
mononucleated cells with some smaller MNGC (3–10 nuclei)
interspersed inmonolayers infected with1BMAA0553 or1TssN
at 24 h. We therefore also infected cells at a higher MOI of 20 and
examined MNGC formation at 24 h (data not shown). At this
higher MOI, we observed pyknotic nuclei and denuded plasma
membranes, in a manner consistent with having formed MNGC
first, and subsequently undergoing cell death, for GRS 23344 and
1TssN, but not for 1BMAA0553. Thus, 1TssN still induced
MNGC formation although at a slower rate than the parental
strain whereas 1BMAA0553 likely is not able to induce MNGC
formation.
Virulence and Immune Responses
We measured the virulence of these mutant strains in a small
particle aerosol challenge model of glanders where BALB/c mice
were exposed to Bm in an aerosolized form. We first showed that
GRS 23344 was able to cause infection in this model. As shown in
Figure 4, whenmice inhaled a measured dose of 4.7×104 CFU of
the parent strain, all mice succumbed to infection by day 7. Based
on estimates that ∼103 CFUs of aerosolized Bm ATCC 23344 is
necessary for an aerosol LD50 with BALB/c mice (Jeddeloh et al.,
2003; Lever et al., 2003), these animals received the equivalent of
50 LD50.
In order to assess the virulence of 1BMAA0553 and 1TssN,
we carried out a preliminary study where we aerosol challenged
BALB/c mice (n = 10) with 8.9 × 103 CFUs (the equivalent
of 9 times the LD50 of ATCC 23344) of 1TssN and observed
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FIGURE 2 | Confocal analysis of the interaction of Burkholderia mallei (Bm) with RAW 264.7 cells. Macrophage-like cells were incubated with GRS 23344
(blue), 1BMAA0553 (orange), or 1TssN (red), stained and then visualized by confocal microscopy. The colocalization of the respective Bm strains with LAMP-1 (A,B)
or actin tails (C,D) was quantified at the times indicated postinfection. The graphs are based on three independent experiments. The number of bacilli counted was
686 for (A), 724 for (B), 673 for (C), and 818 for (D). The columns represent the mean, and bars represent the standard errors. An “**” indicates a significant
difference at p < 0.001.
them for 21 days. All mice survived the aerosol challenge over
that time span and never displayed any clinical signs of disease.
At day 21 no Bm could be recovered from the spleens of
the challenged mice. We repeated the experiment at a higher
dose of 2.1 × 105 CFUs of 1TssN (equivalent to 200 LD50 of
ATCC 23344) with similar results (Figure 4). We then tested
the virulence of 1BMAA0553 using aerosol challenge with a
measured dose of 3.3×104 CFUs (equivalent to 33 LD50 of ATCC
23344), and found that all mice survived over the study period
of 21 days and were symptom free. These results show that the
1BMAA0553 and 1TssN strains are severely attenuated in the
aerosol challenge model.
Antibody Responses and Cytokine Profiles
All mice in the 1TssN or 1BMAA0553 challenge survived
through the 21-day study period. Using an ELISA against
irradiated Bm of the respective challenge strain, we analyzed the
overall IgG antibody response and the IgG subclass (IgG1 and
IgG2a) response from serum samples of all challenged mice and
compared the results to those from naïve mice. We found that
all survivors showed a modest but highly variable IgG response,
with titers of 2972 and 2425 for the 1BMAA0553 and 1TssN
challenges, respectively (Table 1). 1TssN challenges induced a T
helper (Th)1-biased response, with an IgG2a-to-IgG1 ratio of 5.3.
1BMAA0553, by contrast, induced a more balanced Th1/Th2
response with an IgG2a-to-IgG1 ratio of 1.1, attributed largely to
an increased IgG1 response. Naïve mice did not show substantial
antigen-specific antibody titers.
We examined the protein levels of 20 cytokine/chemokines in
the spleen extract supernatant of surviving mice prepared after
the 21-day study period. We considered cytokine/chemokines
that were elevated by at least two-fold relative to levels found
in naïve BALB/c mice as significant. In spleen extracts from
mice challenged with 1BMAA0553, we found 11 cytokines that
were elevated (Figure 5A), including IL-1α, IL-1β, IL-2, IL-5,
IL-6, IL-12, IP-10, MIG, MIP-1α, TNF-α, and VEGF. In spleen
extracts from mice that survived the higher dose challenge of
1TssN, we found 10 cytokines that were elevated (Figure 5B;
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FIGURE 3 | Multinucleated giant cell (MNGC) formation in macrophage-like cells. RAW 264.7 cells were incubated with GRS 23344 (left), 1BMAA0553
(middle), or 1TssN (right) at an MOI of 1 for 6 h (top) and 24 h (bottom) before being stained for actin (white), macrophage nuclei (red) and Bm (green) and then
visualized by confocal microscopy. The yellow arrows indicate the presence of a MNGC. Images are representative of three separate experiments. Scale bar = 20µm.
FIGURE 4 | Survival of BALB/c mice after aerosol exposure. Groups of
mice (n = 10) were challenged by aerosol exposure with GRS 23344 (blue),
1BMAA0553 (orange), or 1TssN (red), and survival was measured over 21
days. The measured inhaled dose was 4.7× 104, 3.3× 104, and 2.1× 105
CFU, for GRS 23344, 1BMAA0553, and 1TssN, respectively.
IL-1α, IL-1β, IL-2, IL-4, IL-10, IL-12, MIG, MIP-1α, TNF-α,
and VEGF). In both cases, these cytokines represent a mixture
of proinflammatory and inflammatory cytokines that included
chemoattractants for cells of the immune system. In both
1BMAA0553 and1TssN challenges, IFNγ levels were increased,
but not to the two-fold threshold (data not shown). The elevated
cytokine levels in these challenged mice 21 days postinfection
show that an innate or cellular immune response appears to have
been mounted in response to 1BMAA0553 and 1TssN aerosol
exposure.
Bacterial Dissemination
To determine the fate of the mutant strains, a dissemination
experiment was performed to compare the mutant1BMAA0553
and 1TssN strains with the parental GRS 23344 strain after
aerosol exposure (n = 5 for each time point). As shown in
Figure 6A, when BALB/c mice were challenged with GRS 23344
(estimated inhaled dose of 4.4× 104 CFU), the bacterial numbers
quickly increase within the lungs by day 1. In addition, Bm was
detected in the spleens for all mice by day 1, and the numbers
increase thereafter (Figure 6B). By day 4, the remaining mice
were eithermoribund (used for CFU recovery) or had succumbed
to infection. Therefore, no mice were available for sampling past
this time point.
In contrast, none of the mice aerosol challenged with either
1BMAA0553 (estimated inhaled dose of 4.4 × 104 CFUs) or
1TssN (estimated inhaled dose of 1.6 × 105 CFUs) showed an
increase in the recovery of CFUs from the lungs (Figure 6A) but
CFUs were still recovered from the organs during the course of
the study. In addition, few CFUs were recovered from the spleens
(Figure 6B). Overall, none of the mice challenged with 1TssN
or 1BMAA0553 displayed any outward clinical signs of disease.
These results demonstrate a defect of these two mutant strains to
replicate in vivo and to successfully disseminate from the lungs in
this mouse inhalation model of infection.
Live-Attenuated Vaccine
LAVs provide a potent means for inducing a durable and
protective immune response by mimicking the infection of more
virulent strains. Given that1TssN showed attenuated pathogenic
phenotypes in vitro and was effectively tolerated in vivo, we
sought to evaluate its potential as a live-attenuated glanders
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TABLE 1 | Antibody responses to 1BMAA0553 and 1TssN after aerosol exposure in BALB/c mice.
Mouse Treatment Antibody titer (SD) Ratio
Group (n) (LD50)* IgG IgG1 IgG2a IgG2a/IgG1
Naïve (10) – <50 (0) <50 (0) <50 (0) –
1BMAA0553 (10) 40 2972 (4972) 1213 (1956) 1131 (1013) 1.1
1TssN (5) 200 2425 (5110) 152 (325) 800 (3175) 5.3
*50% Lethal dose (LD50) values were calculated based on an equivalent dose of Bm ATCC 23344 strain.
FIGURE 5 | Cytokine expression profile. The levels of 20 cytokines/chemokines present in spleen extract supernatants were examined in mice after aerosol
exposure to 1BMA0553 (A) or 1TssN (B) and compared to control mice 21 days postinfection. Only the expression levels of cytokines/chemokines that were at least
two-fold above that of naïve mice are shown. All differences shown are statistically significant at p < 0.001.
vaccine. Because of the modest antibody responses measured in
the initial aerosol exposure experiments using 1TssN, we used
a prime-boost vaccination strategy to boost adaptive immune
responses to1TssN before aerosol challenge with ATCC 23344.
We vaccinated mice (n = 15) two times by aerosol with the
mutant strain1TssN, whereas a second set of mice (n = 10) was
retained as naïve controls and remained untreated. The inhaled
dose of the first vaccination with 1TssN was calculated to be
1.3× 105 CFU. After a period of 21 days, mice showed no sign of
adverse events associated with the infection and were vaccinated
a second time by aerosol. The second inhaled dose was calculated
to be 2.3 × 104 CFU. Mice were followed for 21 days and again
showed no adverse signs of infection. At this time, vaccinated and
naïve control mice were challenged by aerosol with a high dose of
Bm ATCC 23344 strain (4.3× 104 CFUs, or 43 LD50).
As shown in Figure 7A, all naïve mice succumbed to infection
by day 5. In contrast, 67% of the vaccinated mice survived to
day 21. When comparing survival rates between the two groups,
the difference was significant (P < 0.001). In addition, for those
vaccinated mice (n = 5) that did succumb to challenge, the mean
time to death was 8.2 days which was significantly longer (P <
10−4) than the mean time to death of 4.1 days for the control
group.
Despite the increased survival rate for vaccinated mice, we
observed that survivors experienced a significant weight loss
after challenge (Figure 7B). At 2 week postchallenge, vaccinated
animal weights decreased by a mean of 1.7 g (P < 0.05) from
the mean weight before challenge. At 3 week postchallenge,
vaccinated animal weights decreased by a mean of 3.6 g
(P < 10−4) from the mean weight before challenge. For the
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FIGURE 6 | Bacterial dissemination after infection in the lung and spleen in mice. Recovered CFUs from the lung (A) and spleen (B) are shown for time points
ranging from 6h to 6 days after aerosol exposure with parental strain GRS 23344 (blue), or the deletion strains 1BMAA0553 (orange), and 1TssN (red). In mice
challenged with 1BMAA0553, none had >10 CFUs recovered from the spleen.
ten mice that did survive the challenge, five were examined
by histopathology and the remaining five mice were used
to determine if sterile immunity was achieved. As shown in
Figure 7C, we were able to recover Bm CFUs from a majority of
organs tested (lung, liver, and spleen) for all five mice.
Vaccine-Induced Immune Response
Table 2 shows the antibody response to Bm ATCC 23344 21
days after the prime vaccination and 21 days after the boost
vaccination with 1TssN. An ELISA using heat-inactivated Bm
ATCC 23344 showed antibody responses that were comparable to
the modest responses that we previously observed in the aerosol
exposure experiments with 1TssN (Table 1). At 21 days after
the prime vaccination, we saw an average IgG titer of 3658, with
average IgG subclass titers of 1051 and 3185, for IgG1 and IgG2a,
respectively. Surprisingly, at 21 days after the boost vaccination
with 1TssN, we observed that antibody titers were lower than
after the prime vaccination, with average IgG titers of 400 and
average IgG1 and IgG2a titers of 87 and 303, respectively.
Furthermore, we examined cytokine expression in
supernatant following in vitro stimulation by irradiated Bm
of splenocytes prepared from mice after the prime and boost
vaccinations (Supplementary Figure S1). Like the antibody
responses, we did not observe an overall increase of cytokine
expression after the boost vaccination in vaccinated mice.
Overall, these results show only modest antibody and cellular
responses induced by the LAV, suggesting poor immunogenicity
with respect to the adaptive immune response.
Histopathology of Vaccinated Mice
We characterized the histopathology of the lung, liver, and spleen
of vaccinated and challenged mice. After the first vaccination
with 1TssN, lungs of all mice had minimal nonspecific
inflammation. Low to moderate numbers of plasma cells were
observed in thoracic lymph nodes, indicative of humoral
immune stimulation with subsequent antibody production.
Similarly, for mice that received the boost vaccination, the
lungs had minimal to mild inflammation, and the pulmonary
infiltrates of two mice had plasma cells, suggesting prior
humoral stimulation. Lungs of all surviving mice at 21 days
post challenge demonstrated signs of pneumonia characterized
by effacement of the parenchyma by necrotic cellular debris,
pyogranulomatous inflammation, many foamymacrophages and
scattered hyperplastic type II pneumocytes. Representative lung
sections are shown in Figures 8A–C, with low numbers of
lymphocytes and macrophages surrounding bronchioles and
blood vessels at 21 days after primary vaccination (Figure 8A),
increased lymphocytes and macrophages at 21 days after the
boost vaccination (Figure 8B), and necrosis with necrotic cellular
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FIGURE 7 | 1TssN vaccine efficacy against aerosol challenge with
high-dose ATCC 23344 in BALB/c mice. Mice were vaccinated with 1TssN
via aerosol delivery on day 0 and 21 and challenged along with naïve mice via
aerosol exposure on day 42. Survival curves of naïve and vaccinated mice after
aerosol challenge with 43 LD50 of Bm ATCC 23344 over 21 days (A). Body
weights of vaccinated surviving mice at prechallenge, 2 week postchallenge,
and 3 week postchallenge (B). Recovered CFUs from five of the vaccinated
surviving mice at 21 days postchallenge from the lung, liver, and spleen (C).
debris and fibrin and edema in adjacent alveolar spaces in mice
that survived 21 days after challenge (Figure 8C).
The livers of mice after the prime and boost vaccinations
showed minimal to mild inflammation, whereas the livers of
the vaccinated mice that survived WT challenge experienced
extensive necrosis. Figures 8D–F shows representative liver
sections showing minimal inflammation at 21 days after primary
vaccination (Figure 8D), mild hepatocellular degeneration with
infiltration by low numbers of lymphocytes, macrophages and
neutrophils after the boost vaccination (Figure 8E), and a large
focally extensive area of coagulative necrosis at 21 days after
challenge by ATCC 23344 (Figure 8F). The most common
splenic lesion in all mice was minimal to mild expansion of
the white pulp by lymphoid hyperplasia with variable numbers
of plasma cells within the white and red pulp (Figures 8G–I).
However, two mice from the challenged group had necrosis
of the white and red pulp and infiltration of neutrophils in
one case (Figure 8I) and primarily neutrophilic and histiocytic
inflammation in the other case. All of the surviving mice had
plasma cells present within their thoracic lymph nodes (data not
shown), suggesting that exposure to the WT strain may have
provided a boost to immunity.
DISCUSSION
In the present study, we constructed deletion mutants for
BMAA0553 and tssN, characterized their pathogenic phenotypes
in vitro and in vivo, and evaluated the potential of 1TssN as a
LAV in a mouse model for inhalational glanders. In vitro growth
assays in nutrient-limited M9 media revealed no difference
between the parental Bm strain GRS 23344 and 1BMAA0553
and 1TssN mutants, suggesting that these genes do not play
a major role in basic metabolism. Intracellular growth assays
with macrophage-like cells showed that while both the parental
strain and deletion mutants had comparable recovery at 3 h,
both deletion mutants showed a ∼10-fold reduction in growth
at 24 h, indicating that the decreased intracellular survival is
a result of phenotypic changes associated with the host cell
environment and not host cell entry. Microscopy of infected
macrophages revealed that both 1BMAA0553 and 1TssN were
able to undergo phagosomal escape and that 1BMAA0553, but
not 1TssN, showed a marked reduction in actin tail formation,
indicating a defect in intracellular motility. Furthermore, 1TssN
displayed a marked delay in both the size and number of MNGCs
formed in vitro relative to the parent GRS 23344 strain, while
1BMAA0553 was almost entirely unable to form MNGCs.
Both 1BMAA0553 and 1TssN showed significant
attenuation of virulence in BALB/c mice. Mice exposed to
aerosol challenge with 1BMAA0553 or 1TssN, even at high
doses, had 100% survival 21 days postinfection, compared to
mice infected with GRS 23344, which died within 5 days. Both
1BMAA0553 and 1TssN persisted within the lungs following
inhalation, and1TssN was recovered from spleens between days
1–3 for some mice, showing that while these mutants are able
to survive within the lung, they are largely unable to establish a
systemic infection. Analysis of the antibody response of infected
mice revealed a Th1-biased antibody response following 1TssN
infection and a balanced Th1/Th2 response to 1BMAA0553.
These results reflect previous findings that show that Bm live
infection induces a Th1-biased response, whereas nonviable Bm
induces a balanced Th1/Th2 response (Amemiya et al., 2002;
Ulrich et al., 2005) and supports our findings that 1TssN is
able to establish at least a mild infection whereas 1BMAA0553
may be completely avirulent. Cytokine analysis at 21 days
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TABLE 2 | Antibody response to 1TssN vaccination in BALB/c mice.
Treatment Antibody titer (SD) Ratio
Mouse group (CFUs) IgG IgG1 IgG2a IgG1/IgG2a
Naïve – <50 (0) <50 (0) <50 (0) –
1TssN, Prime (day 23) 1.25× 105 3658 (6212) 1051 (6812) 3185 (6365) 3.0
1TssN, Boost (day 44) 2.28× 104 400 (219) 87 (61) 303 (261) 3.5
FIGURE 8 | Histopathology of vaccinated and challenged mice. Histopathology of the lung (A–C), liver (D–F), and spleen (G–I) for mice 21 days after primary
and boost vaccinations with 1TssN, and after challenge with ATCC 23344. Sites of inflammation (filled arrow) and necrosis (hollow arrow) are noted, as well as
relevant bronchioles (B) and blood vessels (V). All images are at ×200 magnification.
postinfection revealed numerous elevated pro-inflammatory
and inflammatory cytokines, including IL-2, IL-12, TNF-α,
and VEGF. A number of these cytokines are markers for
activated macrophages (Martinez and Gordon, 2014), suggesting
engagement of the innate immune response. Furthermore, the
elevated cytokine levels 3 week postinfection shows that despite
the high degree of attenuation, both strains are able to induce a
prolonged innate or cellular immune response. Finally, many of
these cytokines have been previously associated with a protective
immune response in Bm infection, including IL-2 (Whitlock
et al., 2011), IL-12 (Amemiya et al., 2006), and TNF-α (Whitlock
et al., 2008).
Burkholderia Virulence Factor Mechanisms
A number of virulence factors have been previously characterized
in Bm and Bp, including VirAG, a two-component regulatory
system shown to be essential for virulence in Bm (Schell et al.,
2007). Among several virulence gene clusters transcriptionally
activated by VirAG is a cluster of motility-associated genes,
BMAA0747-BMAA0751, which includes the genes bimA, bimB,
bimC, and bimE. Mutations to each of these genes abolish
or modify actin-based tail formation (Stevens et al., 2005b;
Schell et al., 2007; Benanti et al., 2015; Lu et al., 2015),
demonstrating that the interaction of multiple genes is involved
in Bm intracellular motility. Other studies have shown that
bimA mutation does not affect host cell entry or phagosomal
escape (Stevens et al., 2005b) but can modulate MNGC
formation (Benanti et al., 2015). Although we found that deletion
of BMAA0553 abolished actin tail formation, no previously
characterized Bm gene associated with actin-based motility was
essential for MNGC formation and in vivo infectivity, suggesting
that the role of BMAA0553 in virulence extends beyond motility
alone.
A second gene cluster activated by VirAG is BMAA0744-
BMAA0727 (including tssN), which encodes components of a
type 6 secretion system (Schell et al., 2007). Overexpression
of VirAG leads to the secretion of virulence factors, such as
Hcp1 and VgrG1, and experiments in Bp have indicated that
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these genes are also involved in MNGC formation (Burtnick
et al., 2011; Toesca et al., 2014). Although tssN has not been
previously characterized, neighboring, co-expressed, BMAA0729
(tssM) has been extensively studied. tssM is expressed in Bm and
Bp shortly after uptake by macrophage cells (Shalom et al., 2007;
Shanks et al., 2009), has deubiquitinase activity (Shanks et al.,
2009; Burtnick et al., 2014), and is responsible for suppression
of host innate immunity (Tan et al., 2010). However, tssM has
no effect on intracellular survival, is not essential for MNGC
formation and is not required for virulence in hamsters (Shanks
et al., 2009). We found that, unlike tssM (Shalom et al., 2007;
Shanks et al., 2009), tssN deletion was associated with decreased
intracellular survival, reduced or delayed MNGC formation, and
loss of virulence.
Previous bioinformatics analyses indicate that tssN is involved
in host ubiquitination and intracellular signaling and that
BMAA0553 encodes a putative serine/threonine phosphatase
that plays a role in signaling, adhesion, and actin cytoskeletal
rearrangement (Memiševic et al., 2014, 2015). Association of
BMAA0553 with MNGC formation is particularly intriguing
because of its genomic localization far from the T6SS cluster,
which is linked to MNGC formation (Toesca et al., 2014). Toesca
et al. showed that the VgrG C-terminal domain is required for
cell fusion, but they and others suggested that it might not
be sufficient and that additional mechanisms may be involved
(Stone et al., 2014; Toesca et al., 2014). The previously identified
role of BMAA0553 in interaction with host signaling pathways,
adhesion, and actin cytoskeleton rearrangement (Memiševic
et al., 2014, 2015) might be interesting for further study within
the context of MNGC formation, as suggested by our observation
of the loss of this phenotype in1BMAA0553.
LAV and Immune Characteristics of 1TssN
Given the ability of 1TssN to display several pathogenic
phenotypes, such as establishing a lung infection, macrophage
entry, phagosomal escape, intracellular motility, and limited
MNGC formation and as well as the previous association of
tssN with the type 6 secretion system (Schell et al., 2007), we
investigated the use of 1TssN as a glanders LAV. Aerosolized
prime-boost vaccination with 1TssN showed 67% efficacy in
protecting against high-dose (>50 LD50) aerosolized challenge
with Bm ATCC 23344 by 21 days postinfection. Subsequent
analysis showed that despite the protection achieved from acute
Bm infection, all surviving mice had detectable bacteria in the
lungs, spleen, and liver, showing that sterile immunity was not
achieved.
Analysis of antibody and cytokine responses in immunized
mice revealed a modest Th1-biased antibody response that
was comparable with other Bm LAVs (Ulrich et al., 2005) but
were not enhanced during boost immunizations. Stimulation of
splenocytes from vaccinated mice with irradiated 1TssN and
ATCC 23344 showed robust cytokine responses and the cytokine
expression profile for both strains was virtually identical,
underscoring their antigenic similarity. However, we found
no change in the cytokine response in spleen samples from
mice after prime and boost immunizations, suggesting that the
protective immune response induced by1TssN was primarily an
innate response. Interestingly, a previous study (Fernandes et al.,
2007) has shown substantial protective effects of adjuvant alone
to aerosol challenge, even several weeks after immunization,
indicating that innate immunity can play a significant role in
protection in aerosol exposure. Furthermore, a study with aerosol
exposure with the intracellular bacterial pathogen Francisella
tularensis has shown delayed or prolonged innate responses that
are not seen in intradermal or subcutaneous routes of infection
(Conlan et al., 2002).
Although it is difficult to directly compare efficacy results
across studies due the variety of immunization and challenge
models, the 67% protection over 21 days after a high-dose (43
LD50) challenge in BALB/c mice achieved by 1TssN vaccination
observed in this study is comparable with the protection achieved
by other glanders vaccine candidates to aerosol challenge. Ulrich
et al. (2005) using a genetically engineered Bm auxotroph, saw
50% protection against low-dose (5 LD50) and 35% protection
against high-dose (440 LD50) at 28 days. Fernandes et al. (2007)
found 30% efficacy when vaccinating with irradiated Bm and
no efficacy when vaccinating with Bm pilin protein in BALB/c
mice after high-dose (22 LD50) challenge. Likewise, Torres et al.
(2015), using a gold nanoparticle-based subunit vaccine, found
no difference in protection between vaccinated and unvaccinated
rhesus macaques after a low-dose (∼1 LD50) aerosol exposure.
It is important to note that unlike intramuscular,
intraperitoneal, or subcutaneous routes of administration
which directly induce a systemic immune response, aerosol
exposure is localized in the lung, and thus the most relevant
immune responses are likely localized in the lung mucosal
environment. However, directly measuring antibody, cytokine,
or cellular responses in the lung using methods, such as alveolar
lavage, is extremely difficult to perform, especially under
containment conditions. Our use of serum antibodies and spleen
extracts focuses on the systemic immune response and may only
serve as a surrogate for the relevant immune environment in the
lung mucosa.
Characterization of the 1BMAA0553 and 1TssN strains
showed defects in intracellular growth and survival, associated
with a loss of intracellular motility and delayed MNGC
formation, respectively, and was found to have highly attenuated
virulence in vivo. Vaccination with 1TssN followed by high-
dose aerosol challenge showed partial protection against death
associated with acute infection, but failed to prevent the
establishment of chronic infection. Our findings suggest that
a persistent low-level infection of the lung by immunization
of 1TssN induced a delayed or prolonged innate response
that was likely responsible for the observed protection. Such a
response would explain the unusually low antibody response after
boost immunization, as it would rapidly clear the LAV before
a secondary antibody response could be mounted. Despite the
protection achieved in this study, the modest antibody responses
induced by 1TssN limits its potential use as a vaccine candidate,
and instead serves to highlight the role of innate and cellular
immunity in mitigating acute infection in inhalational glanders.
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